What is the purpose of this trial?
A phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with metastatic colorectal cancer (mCRC) who experienced disease progression during or following two lines of treatment.
Eligible patients will be assigned to one of several treatment arms.
F. Hoffman-La Roche Ltd
Start Date: 10/03/2018
End Date: 04/01/2020
Last Updated: 12/02/2018
Study HIC#: 2000023122